10:28 AM EDT, 07/29/2025 (MT Newswires) -- Nektar Therapeutics ( NKTR ) said Tuesday that the US Food and Drug Administration has granted fast track designation to rezpegaldesleukin for the treatment of severe-to-very severe alopecia areata, an autoimmune disease that causes hair loss, in adults and pediatric patients.

The designation supports expedited development for therapies targeting serious conditions with unmet needs, the company said.

Rezpegaldesleukin is being compared to a placebo in a phase 2b study in about 90 patients, with results expected in December, Nektar said.

Price: 23.60, Change: -0.05, Percent Change: -0.21